Nurix Therapeutics Inc · Q3 2022 earnings

Briefing

Nurix reported third quarter fiscal year 2022 financial results

Nurix Therapeutics reported a net loss of $45.7 million for the third quarter ended August 31, 2022. The company's cash, cash equivalents, and marketable securities totaled $413.6 million as of August 31, 2022. They also completed two registered direct offerings in July raising gross proceeds of $95 million.

• Completed two registered direct offerings in July raising gross proceeds of $95 million
• Maintained a strong financial position with $413.6 million in cash and marketable securities as of August 31, 2022
• Expanded leadership team and board of directors with experienced industry leaders
• Announced multiple presentations at upcoming SITC 2022 annual meeting, including initial PK/PD data for NX-1607 program

Headline financials

Revenue & EPS history

Nurix anticipates presenting additional clinical results from the Phase 1a portion of the NX-2127 trial and expects to have initial PK/PD data from the Phase 1a portion of the NX-5948 study by the end of 2022. Nurix anticipates providing a clinical update from the run-in portion of the DeTIL-0255 Phase 1 study by the end of 2022.